Fluoxetine: A Comprehensive Overview Of A Selective Serotonin Reuptake Inhibitor

<br>Fluoxetine, commonly known by the brand name Prozac, is a first-line antidepressant belonging to the class of selective serotonin reuptake inhibitors (SSRIs). Approved by the U.S. Food and Drug Administration (FDA) in 1987, fluoxetine revolutionized the treatment of depression and other psychiatric disorders due to its favorable side effect profile compared to tricyclic antidepressants and monoamine oxidase inhibitors. This report provides a concise overview of fluoxetine’s pharmacology, clinical indications, efficacy, adverse effects, and key considerations in clinical practice.<br><br><br><br>Pharmacology and Mechanism of Action<br><br><br><br>Fluoxetine is a potent and highly selective inhibitor of the serotonin transporter (SERT), located on the presynaptic neuron. By blocking the [https://www.buzznet.com/?s=reuptake reuptake] of serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft, fluoxetine increases the availability of serotonin for postsynaptic receptor binding. This enhancement of serotonergic neurotransmission is believed to underlie its antidepressant and anxiolytic effects. Unlike older antidepressants, fluoxetine has minimal affinity for histaminergic, cholinergic, or adrenergic receptors, reducing the incidence of sedation, anticholinergic effects, and orthostatic hypotension.<br><br><br><br>The drug is absorbed orally with a bioavailability of about 72%. It is extensively metabolized in the liver via the cytochrome P450 enzyme CYP2D6 and, to a lesser extent, CYP2C9 and CYP3A4, producing the active metabolite norfluoxetine, which has a half-life of 4–16 days. The long half-life of fluoxetine (1–4 days) and norfluoxetine (7–15 days) allows for once-daily dosing and provides a gradual withdrawal profile, but also increases the risk of drug interactions and prolongs the time to steady-state concentration (approximately 4–5 weeks).<br><br><br><br>Clinical Indications<br><br><br><br>Fluoxetine is approved for a range of psychiatric conditions in adults and children. Its primary indication is major depressive disorder (MDD), where it is effective in reducing depressive symptoms and preventing relapse. It is also widely used for obsessive-compulsive disorder (OCD) in adults and children aged 7 and  , [https://farmaciazotti.it/images/products/black-cialis.webp https://farmaciazotti.it/images/products/black-cialis.webp], older, bulimia nervosa (moderate to severe), and panic disorder with or without agoraphobia. Off-label uses include social anxiety disorder, premenstrual dysphoric disorder (PMDD), post-traumatic stress disorder (PTSD), and premature ejaculation. In addition, fluoxetine is used in combination with olanzapine (Symbyax) for treatment-resistant depression and bipolar depression.<br><br><br><br>Efficacy<br><br><br><br>Numerous randomized controlled trials and meta-analyses have established fluoxetine’s efficacy in acute and maintenance treatment of MDD. Response rates are approximately 50–60%, with remission rates around 30–40% after 8–12 weeks, comparable to other SSRIs. In OCD, fluoxetine reduces symptom severity by 20–40% on the Yale-Brown Obsessive Compulsive Scale. For bulimia nervosa, it decreases binge-eating and vomiting episodes. However, its onset of therapeutic action typically takes 2–4 weeks, and maximal benefit may require 6–8 weeks.<br><br><br><br>Adverse Effects<br><br><br><br>The side effect profile of fluoxetine is generally milder than that of older antidepressants, but still notable. Common adverse effects include gastrointestinal disturbances (nausea, diarrhea, loss of appetite), insomnia, nervousness, fatigue, headache, and sexual dysfunction (decreased libido, delayed ejaculation, anorgasmia). Weight gain is less pronounced than with other SSRIs like paroxetine, but long-term use may cause modest weight increase. Less common but more serious risks include serotonin syndrome (especially when combined with other serotonergic agents), bleeding disorders due to impaired platelet aggregation, hyponatremia (particularly in elderly or volume-depleted patients), and acute angle-closure glaucoma. In children and adolescents, fluoxetine carries a black-box warning for increased risk of suicidal ideation and behavior during initial treatment; close monitoring is essential.<br><br><br><br>Drug Interactions<br><br><br><br>Fluoxetine’s inhibition of CYP2D6 can significantly increase plasma levels of drugs metabolized by this enzyme, such as tricyclic antidepressants, antipsychotics (e.g., haloperidol, risperidone), beta-blockers (metoprolol), and antiarrhythmics (flecainide, propafenone). Co-administration with monoamine oxidase inhibitors (MAOIs) is contraindicated due to risk of severe serotonin syndrome; a washout period of at least 5 weeks is recommended after stopping fluoxetine before starting an MAOI. Similarly, combination with other SSRIs, SNRIs, triptans, or St. John’s wort requires caution.<br><br><br><br>Special Populations<br><br><br><br>In pregnancy, fluoxetine is categorized as FDA Pregnancy Category C (now replaced by more nuanced labeling). Studies have shown a small increased risk of persistent pulmonary hypertension in the newborn and subtle neurobehavioral effects; however, untreated maternal depression poses its own risks. The drug is excreted in breast milk, but levels are low, and most guidelines consider it acceptable during breastfeeding with monitoring. For elderly patients, lower starting doses (e.g., 10 mg/day) are recommended due to increased sensitivity and risk of hyponatremia. Renal or hepatic impairment may reduce clearance, necessitating dose adjustment.<br><br><br><br>Withdrawal and Discontinuation<br><br><br><br>Because of the long half-life of fluoxetine and its active metabolite, withdrawal symptoms are less common and less severe than with shorter-acting SSRIs like paroxetine or venlafaxine. Nevertheless, abrupt discontinuation can cause dizziness, paresthesias, irritability, anxiety, and flu-like symptoms. Tapering over several weeks is advised.<br><br><br><br>Conclusion<br><br><br><br>Fluoxetine remains a cornerstone in the pharmacotherapy of major depressive disorder and other serotonergic-related conditions. Its favorable side effect profile, once-daily dosing, and long half-life offer advantages for adherence and withdrawal management, though potential for drug interactions and slow onset require careful clinical judgment. Continued research on personalized medicine may optimize its use based on genetic polymorphisms affecting metabolism. Overall, fluoxetine’s efficacy and safety record over three decades make it a valuable tool in psychiatric treatment, balancing benefits against risks in diverse patient populations.<br><br>